Pain Reliever, Acetaminophen USP Caplets, 500 mg, 225-count bottles packaged in a cardboard carto...
FDA Drug Recall #D-0765-2023 — Class II — May 22, 2023
Recall Summary
| Recall Number | D-0765-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | May 22, 2023 |
| Status | Completed |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Aurobindo Pharma USA Inc. |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 87,360 bottles |
Product Description
Pain Reliever, Acetaminophen USP Caplets, 500 mg, 225-count bottles packaged in a cardboard carton, Distributed by: Walgreen Co., 200 Wilmot Rd, Deerfield, IL 60015; NDC 0363-9947-35.
Reason for Recall
Failed Impurities/Degradation Specifications: firm's investigation due to customer complaints for discoloration found that the product was out of specification for an impurity.
Distribution Pattern
The recalled product was distributed to one Retail Distributor (Walgreens) who further distributed Nationwide in the USA.
Lot / Code Information
Lot: P2200101, P2200178, Exp. date 11/2023; P2200230, Exp. date 12/2023
Other Recalls from Aurobindo Pharma USA Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0492-2024 | Class II | Clorazepate Dipotassium Tablets, USP, 7.5 mg, a... | Apr 24, 2024 |
| D-0491-2024 | Class II | Clorazepate Dipotassium Tablets, USP, 3.75 mg, ... | Apr 24, 2024 |
| D-1171-2023 | Class II | Rasagiline Tablets 0.5mg, 30-count bottle, Rx o... | Aug 2, 2023 |
| D-1087-2023 | Class II | Rufinamide Tablets, USP 200 mg, packaged in 120... | Jul 21, 2023 |
| D-1088-2023 | Class II | Rufinamide Tablets, USP 400 mg, packaged in 120... | Jul 21, 2023 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.